Metacare메타케어

Metacare's shares have fallen sharply over the past year, and its reported profit swung to a loss in the first half of 2026.

Metacare, a Seoul-listed company with pharmaceutical, medical device and real estate operations, reported trailing revenue of ₩39.9B and a small operating profit of ₩1.3B for the twelve months to H1 2026, but a net loss of ₩1.6B. Its share price is ₩1,158, down 62.6% over one year, and it carries ₩46.0B in borrowings against ₩11.0B in cash. The data shows a pending merger and convertible bond activity in recent filings, but the terms and effects are not described in the data provided.

What stands out

• Trailing operating margin is 3.4%, but the trailing net margin is -4.0%, so the business made an operating profit while ending in a net loss.
• Revenue was ₩32.8B in 2025 and ₩20.2B in 2024, with large swings in past years, including a loss-making 2023 with operating income of -₩8.9B.
• Borrowings of ₩46.0B are about 77% of equity on a liabilities-to-equity basis, which is a meaningful debt load relative to the company's recent earnings.
• Filings from July to October 2026 include a merger decision, a merger completion report and a decision on acquiring its own convertible bonds before maturity; the data does not explain the details.
• Foreign ownership fell from 0.7% to 0.4% over about 60 days, and 20-day foreign net flows were negative, while retail flows were positive.

What to watch

• Upcoming full-year 2026 results and whether operating profit turns into net profit, since the trailing figures show a net loss.
• The financial effects of the completed merger and the convertible bond buyback, which the data does not detail.
• Debt levels and cash generation, given ₩46.0B of borrowings against ₩11.0B of cash and trailing free cash flow of ₩3.4B.